Immunohematologic consequences of major ABO-mismatched bone marrow transplantation

Area of Science:

• Hematology
• Immunology
• Transplantation

Background:

• Bone marrow transplantation (BMT) involves replacing damaged or diseased bone marrow with healthy stem cells.
• ABO blood group incompatibility between donor and recipient can lead to complications.
• Immunohematologic problems can arise post-transplant, affecting blood cell production and survival.

Purpose of the Study:

• To investigate the incidence and nature of immunohematologic problems in ABO major mismatched BMT.
• To compare the effects of different immunosuppressive regimens on post-transplant complications.

Main Methods:

• Retrospective analysis of 58 patients undergoing BMT from HLA-matched siblings with ABO major mismatches.
• Monitoring of isohemagglutinin titers, reticulocyte counts, and hemoglobin levels post-BMT.
• Comparison of outcomes between patients treated with cyclosporine/prednisone versus methotrexate/prednisone for graft-versus-host disease prophylaxis.

Main Results:

• 21% of evaluable patients (12/58) experienced significant immunohematologic problems.
• Persistent anti-A or anti-B isohemagglutinins were observed in 9 patients beyond 120 days.
• Delayed red cell production (erythropoiesis) occurred in 9 patients, with 5 experiencing delays >170 days.
• Overt hemolysis was noted in 5 patients.
• Hemolysis and delayed erythropoiesis were more frequent in patients receiving cyclosporine/prednisone.

Conclusions:

• ABO major mismatched BMT is associated with substantial immunohematologic consequences.
• Cyclosporine-based immunosuppression may increase the risk of hemolysis and delayed erythropoiesis compared to methotrexate-based regimens.
• Careful monitoring and management are crucial for patients undergoing ABO mismatched BMT.